Portland biotech aims to ease side effects of common treatment By: Portland Business Journal via Business Journals March 09, 2022 at 10:50 AM EST The startup closed a $50 million funding round last year and has three clinical trials in the works. Read More >> Related Stocks: Harbor Disruptive Innovation ETF
